AU Patent

AU2020203967B2 — Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Assigned to Bristol Myers Squibb Co · Expires 2020-10-22 · 6y expired

What this patent protects

This invention relates to methods of treating psoriasis using amide-substituted heterocyclic derivatives, in particular, the compound 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl iH-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide.

USPTO Abstract

This invention relates to methods of treating psoriasis using amide-substituted heterocyclic derivatives, in particular, the compound 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl iH-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020203967B2
Jurisdiction
AU
Classification
—
Expires
2020-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.